The Role of Diet in Influencing the Diversity of Gut Microbiome Related to Lupus Disease Activities: A Systematic Review

Putri, Prisly Z.; Hamijoyo, Laniyati; Sahiratmadja, Edhyana

doi:https://doi.org/10.1155/2022/6908677

International Journal of Microbiology

On this page

Abstract Introduction Materials and Methods Results Discussion Conclusions Data Availability Conflicts of Interest Acknowledgments References Copyright Related Articles

Review Article | Open Access

Volume 2022 | Article ID 6908677 | https://doi.org/10.1155/2022/6908677

The Role of Diet in Influencing the Diversity of Gut Microbiome Related to Lupus Disease Activities: A Systematic Review

Prisly Z. Putri,¹Laniyati Hamijoyo,^2,3and Edhyana Sahiratmadja⁴

Academic Editor: Todd R. Callaway

Received15 Aug 2022

Revised26 Nov 2022

Accepted10 Dec 2022

Published31 Dec 2022

Abstract

Gut microbiome dysbiosis can affect the host immune system. The balance and activity of the gut microbiome, which are influenced by daily diet, might be associated with disease activity in systemic lupus erythematosus (SLE). Therefore, we conducted a systematic review based on the PRISMA guideline to explore the role and types of diet that affects the gut microbiome related to changes in SLE disease activity. All original and full-text English articles in the last ten years were included using predefined keywords according to PEO (population, exposure, and outcome) design in PubMed. The study subjects were carefully analyzed, including lupus-susceptible mice and humans with SLE on various diets. Children and pregnant women populations were excluded. Of 134 studies found, only seven full-text articles had met the inclusion criteria of which only one study conducted in human. This human study showed that dietary polyphenol as dihydrochalcones and flavanones affected the gut microbiome and ameliorated lupus disease activity. On the contrary, dietary flavones increased Blautia (family: Lachnospiraceae), and that often found in active lupus diseases. Furthermore, six studies in lupus-prone mice models showed that resistant starch (RS), retinoic acid (RA) or all-trans retinoic acid (tRA), and acidic water (AW) had influenced the gut microbiome, leading to an improved lupus development. Conversely, the 2018 commercial rodent diet, vitamin A-retinoic acid (VARA), neutral water (NW), and high tryptophan diet had impacted various microbiomes, resulting in increased lupus activity. Interestingly, several diets have the effect of either increasing or decreasing lupus disease activity depending on the microbiome they affect, such as AW associated with Turicibacter spp., which is frequently found in active lupus disease, and tRA in Bacteroidetes associated with renal pathology. To conclude, diet can influence the gut microbiome, which is related to the disease activity process of SLE.

1. Introduction

Systemic lupus erythematosus (SLE) is an autoimmune disease resulting from a loss of immune tolerance. About 0.3 to 23.7 per 100,000 individuals globally have been diagnosed with SLE yearly. The prevalence varies from 6.5 to 178.0 per 100,000 population, predominantly in productive-age women and more frequent in adults than children [1, 2].

SLE is a unique disease with various atypical manifestations, making it challenging to recognize, prevent, and treat [1, 3]. On the other hand, the pathogenesis of SLE is still unclear and multifactorial [4]. The environmental triggers play an important role in SLE development in genetically susceptible individuals, including hormones (e.g., prolactin and estrogen), drugs (e.g., oral contraceptive and postmenopausal hormone therapy), UV light, infections (e.g., cytomegalovirus and Ebstein–Barr virus), toxins (e.g., silica dust), and cigarette smoking, as well as dietary factors and gut microbiota [5, 6].

In the last 20 years, many studies on a diet have been associated with SLE and offer a promising alternative treatment as it has many advantages in improving the quality of life to the potential for prophylactic effects [7–10]. Nowadays, the microbiome is a hot topic in research as it influences the physiology or pathology of the host. Dysbiosis or imbalance of the microbiome is a variation of the gut microbial composition in the shape of loss of beneficial organisms and overgrowth of harmful organisms, leading to loss of microbial diversity. Dysbiosis can affect the regulation of the development and function of the immune system, which may play a role in the development of autoimmune diseases such as SLE [11]. Further dysbiosis can damage the intestinal barrier by penetration of living bacteria or removal of dead bacterial components outside the intestine [12, 13]. A study on childbearing-age female lupus-prone mice has shown an increase in Lachnospiraceae and a decrease in Lactobacilli [14]. Of note, the prevalence of human SLE is predominated (99%) in female in their child-bearing age; therefore, microbiome disbalance plays a role as a risk factor in SLE development. At the microbiome level, dietary factors are determined by several factors, among others, the type of diet.

At the microbiome level, dietary factors are determined by several factors, among others, the type of diet. One of the roles of diets’ pattern or types is its effect on the formation of inflammatory or anti-inflammatory metabolites [15]. The correct diet in SLE patients can improve body homeostasis, prevent medication side effects, increase the period of remission, and improve physical and mental well-being [9]. For example, high fiber in the Mediterranean diet has been shown to reduce the risk of CVD and inflammatory markers, as well as to improve anthropometric profiles in SLE patients [16–19]. Clinical complication and comorbidities resulting from SLE therapy, can also be controlled with a diet; for example, diet with high vitamins, minerals, monounsaturated fatty acid (MUFA), or polyunsaturated fatty acid (PUFA) with moderate energy consumption [20, 21]. Inappropriate dietary intake shows worsening SLE disease activity due to changes in the microbiome’s composition through increased inflammation and the effect of its antigen [14]. A Western diet low in fiber, high in sugar and fat, and rich in processed foods can worsen SLE activity by altering the diversity of the gut microbiome and disrupting the intestinal barrier [22, 23]. Furthermore, the influence of SLE treatment on gut microbiome might also play a pivotal role, such as the use of steroids, immunosuppressive drugs, and hydroxychloroquine. The precise mechanism by which diet influences the SLE disease process is still not fully elucidated, and there is little literature relating to the influence of diet on the gut microbiome. Therefore, this review has explored and discussed in more detail the type and the role of diet in influencing the gut microbiome associated with SLE disease activity. The results of this study might provide information for future research in nutritional interventions for SLE patients.

2. Materials and Methods

2.1. Search Strategy and Study Selection

This systematic review was conducted according to the PRISMA guideline. The literature source search was carried out using electronic data of PubMed until the end of August 2021. The keyword was searched according to PEO (population, exposure, and outcome) design; the population was the microbiome in patients with systemic lupus erythematosus, the exposure refers to dietary factors, and the outcome was in the form of SLE disease activity. The keywords had been linked using the Boolean operator, as follows: (((diet) OR (dietary factor) OR (nutrition) OR (dietary intervention) OR (carbohydrate) OR (protein) OR (vitamin) OR (fiber) OR (mineral)) AND ((microbiome) OR (gut microbiome) OR (gut microbiota) OR (microbiota)) AND ((lupus) OR (SLE) OR (systemic lupus erythematosus) OR (human lupus))). In addition, we included all original full-text research articles in English within the last ten years, and as subjects were human and mice models of SLE.

Interventions in the form of diets that influence the gut microbiome targeting changes in SLE disease activity were included with no restrictions, especially on types of diet. Outcomes were measured by the changes in the gut microbiome and identified changes in the SLE disease process. A beneficial effect existed when dietary intake affecting the gut microbiome might ameliorate lupus disease activity. On the other hand, an adverse effect occurred when diet influencing the gut microbiome worsens SLE activity. The exclusion criteria of the articles were children and pregnant women. Articles found with relevant titles were reviewed for abstracts, and then a full-text review was conducted.

2.2. Data Extraction and Quality Assessment

The full texts from included articles were extracted into a table, consisting of collected various data on authors, year, research design, population, exposure, target phyla/genera/families/other, indicators for assessing SLE activity, and study results. The assessment of the quality of the articles was carried out using Joanna Briggs Institute’s critical appraisal tools from the Faculty of Health and Medical Sciences of the University of Adelaide to determine the clarity and focus of the discussion on the research, the validity of the methods used, and the importance and usefulness of the research result [24]. Several questions were given that had to be filled in with “Yes,” “No,” “Unclear,” or “Not applicable” answers.

3. Results

3.1. Study Selection

A qualitative synthesis was conducted with a critical appraisal first. In total, 134 articles were found in the PubMed database. However, only seven articles were relevant to our study, including six experimental studies using lupus-prone mice models and only 1 study using human SLE (Figure 1) [14, 25–30]. The other articles (n = 127) were excluded due to review study design (n = 59), comment articles (n = 3), opinion (n = 1), paediatric population (n = 3), and pregnant women population (n = 1). The other articles (n = 60) were irrelevant or off-topic because they did not answer research questions, discussed other diseases, or used other terminology of lupus related to wolf or Canis lupus familiaris.

3.2. Study Characteristics and Outcomes

The only study with human SLE found in the literature search was a case-control study, including female SLE patients without active disease at the time of sampling. Furthermore, they were not taking antibiotics, glucocorticoids, immunosuppressive drugs, monoclonal antibodies, or other immunotherapy. Additionally, antimalarial drugs and non-steroidal anti-inflammatory drugs were used regularly by 18 of the 20 participants [25].

Furthermore, various types of lupus mice models had been used in experimental studies, such as MRL/Mp-Faslpr (MRL/lpr) mice, pristane-treated Balb/c mice, lupus-prone TLR7.1Tg C57BL/6 (TLR7.1Tg) mice, SWR X NZB F1 (SNF1) mice, and triple congenic lupus-prone mice (B6.Sle1.Sle2.Sle3) stimulated (TC mice), of which five studies considered female mice [26–30], and one study was on both genders [14]. All lupus mice models were not treated for SLE.

Variations of diet composition in this study focused on polyphenols (dihydrochalcones, flavanones, and flavone), vitamin A (RA/tRA and VARA), resistant starch (RS), high tryptophan diet, pH water (acidic water/AW and neutral water/NW), and 2018 commercial rodent diet or isoflavone-richsoy-based diet (2018 diet). Due to dietary intervention, gut microbiota had changed significantly in composition, quality, and quantity. Microbiota was analyzed in all studies, using DNA taken from fecal or gut samples. The main characteristics of the studies about diet that affect the gut microbiome related to SLE disease activity are summarized in Table 1.

A beneficial effect was demonstrated in human SLE by dihydrochalcones with Bifidobacterium, as well as flavanones in human SLE and RA in MRL/lpr mice on Lactobacillus. Moreover, RS diet in TLR7.1Tg and tRA treatment in pristine-treated lupus mice also had a beneficial effect on Clostridiales. Furthermore, RA and VARA diets had a beneficial effect on Erysipelotrichaceae in MRL/lpr mice. The AW-fed SNF1 mice at the prenephritic stage had a beneficial effect on Lactobacillus members (L. hayakitensis, L. intermedius, L. siliginis, and L. equi), Christensenellaceae, Clostridiales (Ruminococcus gnavus, Peptoniphilus coxii, Caloramator mitchellensis, and Peptoniphilus methioninivorax), Cyanobacteria (Trichodesmium hildebrandti), Proteobacteria (Hydrocarboniphaga daqingensis), and Bacteroidetes (Polaribacter butkevichii) (Figure 2).

An adverse effect occurred when diet affected the gut microbiome, resulting in increased SLE activity as indicated by the intake of polyphenols in the form of flavones in SLE patients that affect Blautia. In SLE mice models, the VARA and 2018 diet had an adverse effect on Lachnospiraceae in MRL/lpr mice. Interestingly, VARA in MRL/lpr mice and SNF1 mice fed NW at the prenephritic stage had an adverse effect on Rikenellaceae. The SNF1 mice fed NW also had an adverse effect on Pedobacter kwangyangensis and Flavobacterium antarcticum at the prenephritic stage. Also, AW-fed SNF1 mice in the nephritic stage on Turicibacter spp. and L. reuteri. Moreover, high tryptophan diet in TC mice had an adverse effect on L. reuteri, L. johnsonii, Bacteroides dorei, Prevotella, and Prevotellaceae, and tRA diet in Balb/c mice treated with pristane-affected Firmicutes/Bacteroidetes ratio (Figure 3).

4. Discussion

Only a few studies, seven qualified in this systematic review, have been identified to fill in the gaps, since the relationship between the diet-gutmicrobiome-autoimmune diseases is relatively recent. This systematic review has proven that certain diets may influence the microbial profile and affect disease activity in SLE patients or experimental lupus-prone mice. Diet and immunity have complex interrelationships. Nutritional needs and metabolism, as well as physiological responses to food, are influenced by immunity [15]. The microbiome, designated as microorganisms and their ecosystems in the intestine, must be in a balanced number and location. Inflammation or autoimmune disease development can occur when the balance is not reached [12].

4.1. Diet That Affects the Gut Microbiome and Its Association with Ameliorating SLE Disease Activity

In SLE, dysbiosis occurs as loss of beneficial organisms, overgrowth of harmful organisms, and loss of microbial diversity [31]. Intake of polyphenols with dihydrochalcones from the regular diet, exclusively apple, in female SLE patients is positively associated with Bifidobacterium [25]. This genus has anti-inflammatory properties, and one of its strains, B. infantis, has an immunoregulatory effect on lymphocytes, epithelial cells, and dendritic cells [32]. In SLE patients, Bifidobacterium can maintain the balance of Tregs, Th17, and Th1 as well as prevent the overactivation of CD4+ lymphocytes [33]. Bifidobacterium, an SCFA-producing bacterium, as a probiotic, can maintain the gut and the balance of gastrointestinal microbiota through changes in intestinal pH, produce antimicrobial substances, compete for nutrients, and reduce intestinal lipopolysaccharide levels [33, 34].

Diet with flavanones (mainly from oranges and their products) in SLE patients and RA diet in MRL/lpr mice have shown a positive relationship with Lactobacillus, which was decreased in MRL/lpr lupus-prone mice. This relationship negatively correlates with lupus disease parameters (lymphadenopathy and glomerulonephritis) and relieves inflammatory flares in lupus patients [14, 25]. This protective mechanism, produced by lactic acid-producing bacteria, Lactobacilli, may occur due to increased immunoregulation by dendritic cells, such as increased Treg balance costimulatory molecules [35]. In addition, there is an increase in the production of anti-inflammatory cytokines (IL-10) which can inhibit the production of IFN-γ-induced autoantibodies and clinical nephritis [35, 36].

A decrease in Clostridiales (class: Clostridia; phylum: Firmicutes) occurred in TLR7.1Tg lupus-prone mice and could be increased by resistant starch (RS) diet [26]. Clostridiales can ferment RS into short-chain fatty acids (SCFAs), thereby inhibiting the pathogenesis of lupus by decreasing IFN-I signalling and pDC. SCFAs also improve the integrity of the epithelial barrier, thereby reducing translocation and growth of lupus-prone bacteria such as L. reuteri, especially in mesenteric lymph node complex (MLN), liver, and spleen [26, 37]. Fermentation sites mainly occur in the distal jejunum, cecum, and proximal colon with SCFA metabolites such as acetate, propionate, and butyrate [38].

Resistant starch (RS) is a type of fiber that can suppress lupus-related pathogenesis and mortality and consists of a carbohydrate source in the form of plant oligosaccharides and polysaccharides that cannot be digested in the small intestine [26]. Dietary patterns associated with high fiber intakes, such as vegetables, fruit, and whole grains, have been found in the Mediterranean diet (Med Diet) [16, 39]. A good prognosis is shown in SLE patients with Med Diet, as evidenced by an excellent anthropometric profile, a reduced risk of CVD, and inflammatory markers. The decrease in SLEDAI scores was also shown to be associated with the consumption of fruits, vegetables, olive oil, sofrito, nuts, fish, and nuts, as well as the abstinence from red meat, meat products, sweet foods, and pastries in the Med Diet component, enabling the contribution of the gut microbiota [16].

An increase in the order Clostridiales and the genus Clostridium has been demonstrated by pristane-induced lupus mice, given tRA (all-trans-retinoic acid) at week two after pristane injection. Although the administration of tRA in the progressive phase of lupus can increase the infiltration of inflammatory cells in the tissues, it shows the immunosuppressant function in the kidneys by reducing glomerulonephritis [29].

The presence of the Erysipelotrichaceae family, which belongs to the Firmicutes phylum, in MRL/lpr lupus mice depends on gender. There is a decrease in female mice, inversely proportional to male mice [14]. Interestingly, this Erysipelotrichaceae family is increased significantly in female SLE patients [40]. Treatment using vitamin A in the form of RA and VARA can lower the level of Erysipelotrichaceae [14]. Furthermore, increased inflammation in the intestine is directly proportional to Erysipelotrichaceae [41].

In the prenephritic 12-week-old SNF1 mice, AW recipients can enhance several microbiomes such as members of Lactobacillus (L. hayakitensis, L. intermedius, L. siliginis, and L. equi), Christensenellaceae, and Clostridiales such as Ruminococcus gnavus, Peptoniphilus coxii, Caloramator mitchellensis, and Peptoniphilus methioninivorax. These changes have implications for the increase in the Firmicutes phylum and contribute to improving the Firmicutes/Bacteroidetes ratio previously decreased in SLE.

Several phyla, such as cyanobacteria member Trichodesmium hildebrandti, Proteobacteria member Hydrocarboniphaga daqingensis, and Bacteroidetes member Polaribacter butkevichii, are also increased in AW-fed prenephritic stage SNF1 mice [30]. Although the mechanism of involvement of the gut microbiome is not precisely known, the rate of disease progression such as nephritis severity (measured by grading proteinuria and proinflammatory cytokines), are lower levels in AW recipients than in NW-recipients mice. The production of autoantibodies against DNA (e.g., total serum IgG anti-dsDNA, IgG2a, and IgM) or against nucleohistone complex (e.g., IgG2 and IgM) are at lower levels in AW recipients than in recipient NW, the potential for immune cell infiltration and glomerular necrosis is also low.

4.2. Diet Influences the Gut Microbiome and Is Associated with Worsening Disease Activity in SLE

The higher levels of Lachnospiraceae are a characteristic of gut microbiota changes in lupus-susceptible MRL/lpr and B6/lpr mice at specific points during lupus progression. In female SLE patients, genus Blautia (family: Lachnospiraceae) was positively associated with flavone intake, of which the main contributors were oranges and their products. However, flavone-rich foods must be present in a combined whole diet to predict the proportion of Blautia [25]. Studies in SLE patients with active lupus disease have shown increased levels of Blautia [43].

Retinol mixed with retinyl palmitate, VARA, significantly increased levels of Lachnospiraceae and correspondingly increased lupus disease parameters such as lymphadenopathy and renal pathology in MRL/lpr mice [14]. The 2018 commercial rodent diet, which contains phytoestrogenic isoflavone-richsoy-based chow diet, also increases Lachnospiraceae related to glomerulonephritis and more severe lupus disease in MRL/lpr mice [28]. Phytoestrogens are estrogen-like substances of plant origin and can produce either good or bad effects on the development of SLE, depending on the estrogen receptor they affect [44]. Proinflammatory effect is associated with increased estrogen receptor alpha (ERα) in lupus-prone models [45]. The difference in fiber sources between the 2018 diet with RD diet and 7013 diets is thought to be the cause of the difference in the abundance of Lachnospiraceae, where the 2018 diet used a mixture of soluble and insoluble fiber derived from plants. [28].

As part of the XIVa cluster of Clostridia, Lachnospiraceae (including Blautia) can promote the accumulation of mucosal Treg cells, anti-inflammatory, and maintain intestinal health through butyrate [46]. However, Fas^lpr mutations can lead to impaired butyrate-associated T cell apoptosis, so the inflammation in MRL/lpr and B6/lpr mice cannot be controlled by Lachnospiraceae, leading to increased SLE disease activity [14, 47].

Another lupus-enriched family in MRL/lpr mice was Rikenellaceae (phylum: Bacteroidetes), further enhanced by the VARA diet and associated with more rapid lupus progression [14]. This was also demonstrated by NW in the prenephritic stage of SNF1 mice [30]. An increase in Pedobacter kwangyangensis and Flavobacterium antarcticum species (phylum: Bacteroidetes) has been shown at the prenephritic stage of NW-recipient SNF1 mice [30]. A significant increase in the phylum Bacteroidetes that contributes to a decrease in the Firmicutes/Bacteroidetes ratio is associated with several inflammatory diseases [48, 49]. In autoimmune diseases, the development of inflammation and the outcome of the disease can be influenced by the balance of microorganisms; therefore, disease progression in pH water recipients may be gut microbiome-dependent [50]. This is evidenced by the suppression of disease progression, including low autoantibody level and proteinuria in NW recipients who have been given the cecum microbiota of AW recipients orally through microbiota manipulation [30].

Turicibacter spp., as a part of the family Erysipelotrichaceae, is positively associated with administering acidic water (AW) in the nephritic stage of SNF₁lupus-prone mice [30]. In MRL/lpr mice, this genus is included in the top ten genera with the highest level and is a biomarker in the GF + SLE group [51, 52].

An increase in L. reuteri is also demonstrated in AW-fed nephritic stage SNF1 mice and high tryptophan diet in TC mice [26, 30]. Environmental and genetic influences play a significant role in the response of L. reuteri. Despite its potential as a probiotic through its anti-inflammatory and Treg-inducing properties, the increased growth of L. reuteri has the potential for translocation, which may induce the pathogenesis of lupus related to organ pathology and pDC/IFN triggering properties [27, 37].

A high tryptophan diet in TC mice can also increase L. johnsonii, where these taxa have been thought to increase after developing autoimmunity that can exacerbate lupus. In different lupus-susceptible mouse models, the effect of Lactobacillus spp. abundance will also be different as in TLR7.1Tg and TC mice; the more Lactobacillus spp., the worse the activity of SLE disease [27]. An increase in the abundance of Bacteroides dorei, Prevotella, and Prevotellaceae (phylum Bacteroidetes) has also occurred in TC mice with a high tryptophan diet [26]. The formation of indole derivative metabolites from tryptophan can be carried out by Gram-negative bacteria such as Bacteroides spp., which can negatively affect TC mouse immune cells [26, 53, 54]. On the other hand, tryptophan can be converted to kynurenine by indoleamine 2,3-dioxygenase (IDO) and is regulated by IFN-1, a cytokine that is increased in SLE patients. This increased conversion can lower serotonin levels in serum, leading to a severe SLE phenotype with elevated anti-dsDNA antibodies and nephritis as demonstrated in TC mice [26, 55]. Sources of tryptophan are high-protein foods such as eggs, meat, fish, beans, nuts, and cheese [53].

In pristane-treated Balb/c mice, to demonstrate the phenotypes of lupus, administration of tRA at week ten after pristane injection has resulted in an increase in Bacteroidetes associated with worsening glomerular pathological scores and proteinuria [29]. In addition, there is also a decrease in Firmicutes, which contributed to a decrease in the Firmicutes/Bacteroidetes ratio, as happened in SLE patients compared to healthy controls [29, 56]. This suggests that the tRA diet can positively and negatively affect SLE activity depending on the administration time. The worsening effect of diet on various microbiomes is depicted in Figure 3.

4.3. Diet and Metabolic Function of the Microbiome

In addition to microbial composition, diet can also impact the metabolic function of the microbiome. In the gut microbiome of MRL/lpr mice treated with RA, there is a change in genes in carbohydrate metabolism (glycoxylate, galactose, and dicarboxylate). In contrast, there is a decrease in galactose metabolism and glycolysis and an increase in glycoxylate and dicarboxylate metabolism in lupus disease [14]. The metabolism of amino acids such as histidine, phenylalanine, tyrosine, and tryptophan can also be affected by RA treatment, so these metabolic changes indicate weakening of lupus symptoms [14]. On the other hand, through metagenomic prediction of microbial metabolic function, there is a decrease in genetic information processing and nucleotide metabolism as well as significant increases in membrane transport, signal transduction, cell motility, and sporulation genes which can be exacerbated by VARA treatment and worsening disease [14].

Diet is not the only definite factor that influences the course of SLE disease related to changes in the microbiome. Another factor that must be considered is the use of drugs in SLE patients. The decrease in Firmicutes and Enterococcaceae occurred with hydroxychloroquine (HCQ), both short-term/high-dose and long-term [57–59]. As an anti-inflammatory and immunosuppressive agent, glucocorticoid therapy is not only capable of reducing cytokine production but also has the potential to stabilize the gut microbiome, which is characterized by a decrease in Bacteroidetes with an increase in Lactobacillus, Streptococcus, and Bifidobacterium [60]. However, in the human study, there has been no further discussion of the effects of antimalarial drugs and non-steroidalanti-inflammatory drugs on microbiome activity.

The limitation of this systematic review is that most research subjects have used animal-prone lupus models with varied types and genders, and only one study has included SLE patients. In addition, all eligible studies did not use uniform tools to measure lupus disease activity. However, SLE development might be seen through lupus disease parameters such as antibody responses, organ pathology, gut leakiness or bacterial translocation, microbiota manipulation or transfer, and change in microbiome metabolic functions. Interestingly, even dysbiosis itself has become a parameter of SLE activity [61]. Moreover, this study only focused on the effect of diet on microbiome activity in SLE patients without considering the current treatment. Further studies exploring factors related to the axis of diet-microbiome-SLE disease activity are of greatly needed. Moreover, considering the drugs interaction involving microbiome in SLE therapy maybe enhance the quality of life of SLE patients.

5. Conclusions

The nutrient-gut microbiome relationship has a significant role in the pathology of systemic lupus erythematosus (SLE). Resistant starch (RS) diet from fibrous foods can be fermented by the gut microbiome into several types and amounts of short-chain fatty acids (SCFAs) and have a beneficial effect on SLE outcomes in lupus-prone mice models. Moreover, polyphenols, especially from apples and oranges, can increase beneficial microorganisms in SLE patients. These findings suggested a new therapeutic approach through dietary intervention to treat autoimmune diseases.

Data Availability

The data used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Acknowledgments

This study was funded by the Ministry of Research, Technology and Higher Education, Republic of Indonesia. The authors would like to thank Dr. Syamsunarno MRAA, Dr. Hanna, and Dr. Megantara I for reviewing this article.

References

M. Washio, C. Kiyohara, and A. Ohta, in Epidemiology of systemic lupus erythematosus, Intechopen, London, UK, 2019.
View at: Publisher Site
G. J. Pons-Estel, M. F. Ugarte-Gil, and G. S. Alarcón, “Epidemiology of systemic lupus erythematosus,” Expert Review of Clinical Immunology, vol. 13, no. 8, pp. 799–814, 2017.
View at: Publisher Site | Google Scholar
S. A. Yeoh, S. S. Dias, and D. A. Isenberg, “Advances in systemic lupus erythematosus,” Medicine (Baltimore), vol. 46, no. 2, pp. 84–92, 2018.
View at: Publisher Site | Google Scholar
Q. Mu, H. Zhang, and X. M. Luo, “SLE: another autoimmune disorder influenced by microbes and diet?” Frontiers in Immunology, vol. 6, pp. 608–610, 2015.
View at: Publisher Site | Google Scholar
S. González, I. Gutiérrez-Diaz, P. Lopez et al., “Microbiota and oxidant-antioxidant balance in systemic lupus erythematosus,” Nutricion Hospitalaria, vol. 34, no. 4, pp. 934–941, 2017.
View at: Publisher Site | Google Scholar
M. Barbhaiya and K. H. Costenbader, “Environmental exposures and the development of systemic lupus erythematosus,” Current Opinion in Rheumatology, vol. 176, no. 12, pp. 139–148, 2016.
View at: Google Scholar
M. Aparicio-Soto, M. Sánchez-Hidalgo, and C. Alarcón-De-La-Lastra, “An update on diet and nutritional factors in systemic lupus erythematosus management,” Nutrition Research Reviews, vol. 30, no. 1, pp. 118–137, 2017.
View at: Publisher Site | Google Scholar
M. A. Islam, S. S. Khandker, P. J. Kotyla, and R. Hassan, “Immunomodulatory effects of diet and nutrients in systemic lupus erythematosus (SLE): a systematic review,” Frontiers in Immunology, vol. 11, pp. 1477–1517, 2020.
View at: Publisher Site | Google Scholar
M. M. Constantin, I. E. Nita, R. Olteanu et al., Experimental and Therapeutic Medicine, vol. 17, no. 2, pp. 1085–1090, 2019.
View at: Publisher Site
M. C. S. de Medeiros, J. C. A. Medeiros, H. J. de Medeiros, J. C. G. d C. Leitão, and M. I. Knackfuss, “Dietary intervention and health in patients with systemic lupus erythematosus: a systematic review of the evidence,” Critical Reviews in Food Science and Nutrition, vol. 59, no. 16, pp. 2666–2673, 2019.
View at: Publisher Site | Google Scholar
H. Xu, M. Liu, J. Cao et al., “The dynamic interplay between the gut microbiota and autoimmune diseases,” Journal of Immunology Research, vol. 2019, pp. 1–14, 2019.
View at: Publisher Site | Google Scholar
G. J. Silverman, D. F. Azzouz, and A. V. Alekseyenko, “Systemic Lupus Erythematosus and dysbiosis in the microbiome: cause or effect or both?” Current Opinion in Immunology, vol. 61, pp. 80–85, 2019.
View at: Publisher Site | Google Scholar
G. L. V. de Oliveira, “The gut microbiome in autoimmune diseases,” in Microbiome and Metabolome in Diagnosis, Therapy, and Other Strategic Applications, pp. 325–332, Elsevier, Amsterdam, Netherlands, 2019.
View at: Google Scholar
H. Zhang, X. Liao, J. B. Sparks, X. M. Luo, V. Tech, and X. M. Luo, “Dynamics of gut microbiota in autoimmune lupus,” Applied and Environmental Microbiology, vol. 80, no. 24, pp. 7551–7560, 2014.
View at: Publisher Site | Google Scholar
C. Venter, S. Eyerich, T. Sarin, and K. C. Klatt, “Nutrition and the immune system: a complicated tango,” Nutrients, vol. 12, no. 3, p. 818, 2020.
View at: Publisher Site | Google Scholar
G. Pocovi-Gerardino, M. Correa-Rodríguez, J. L. Callejas-Rubio et al., “Beneficial effect of Mediterranean diet on disease activity and cardiovascular risk in systemic lupus erythematosus patients: a cross-sectional study,” Rheumatology, vol. 60, no. 1, pp. 160–169, 2021.
View at: Publisher Site | Google Scholar
A. Cárdeno, M. Sánchez-Hidalgo, and C. Alarcón-de-la-Lastra, “An up-date of olive oil phenols in inflammation and cancer: molecular mechanisms and clinical implications,” Current Medicinal Chemistry, vol. 20, no. 37, pp. 4758–4776, 2013.
View at: Publisher Site | Google Scholar
R. Casas, E. Sacanella, and R. Estruch, “The immune protective effect of the mediterranean diet against chronic low-grade inflammatory diseases,” Endocrine, Metabolic & Immune Disorders - Drug Targets, vol. 14, no. 4, pp. 245–254, 2014.
View at: Publisher Site | Google Scholar
G. McKellar, E. Morrison, A. McEntegart et al., “A pilot study of a Mediterranean-type diet intervention in female patients with rheumatoid arthritis living in areas of social deprivation in Glasgow,” Annals of the Rheumatic Diseases, vol. 66, no. 9, pp. 1239–1243, 2007.
View at: Publisher Site | Google Scholar
Y. Minami, T. Sasaki, Y. Arai, Y. Kurisu, and S. Hisamichi, “Diet and systemic lupus erythematosus: a 4 year prospective study of Japanese patients,” Journal of Rheumatology, vol. 30, no. 4, pp. 747–754, 2003.
View at: Google Scholar
M. C. Borges, F. d M. M. dos Santos, R. W. Telles, C. C. D. Lanna, and M. I. T. D. Correia, “Nutritional status and food intake in patients with systemic lupus erythematosus,” Nutrition, vol. 28, no. 11–12, pp. 1098–1103, 2012.
View at: Publisher Site | Google Scholar
K. M. Maslowski and C. R. Mackay, “Diet, gut microbiota and immune responses,” Nature Immunology, vol. 12, no. 1, pp. 5–9, 2011.
View at: Publisher Site | Google Scholar
M. S. Desai, A. M. Seekatz, N. M. Koropatkin et al., “A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility,” Cell, vol. 167, no. 5, pp. 1339–1353, 2016.
View at: Publisher Site | Google Scholar
E. Naik, R. Mhaskar, P. Emmanuel, S. Mishra, S. Patel, and A. Kumar, “Critical appraisal skills are essential to informed decision-making,” Indian Journal of Sexually Transmitted Diseases and AIDS, vol. 30, no. 2, pp. 112–119, 2009.
View at: Publisher Site | Google Scholar
A. Cuervo, A. Hevia, P. López et al., “Association of polyphenols from oranges and apples with specific intestinal microorganisms in systemic lupus erythematosus patients,” Nutrients, vol. 7, no. 2, pp. 1301–1317, 2015.
View at: Publisher Site | Google Scholar
S. C. Choi, J. Brown, M. Gong et al., “Gut microbiota dysbiosis and altered tryptophan catabolism contribute to autoimmunity in lupus-susceptible mice,” Science Translational Medicine, vol. 12, no. 551, Article ID eaax2220, 2020.
View at: Publisher Site | Google Scholar
D. F. Zegarra-Ruiz, A. El Beidaq, A. J. Iñiguez et al., “A diet-sensitive commensal Lactobacillus strain mediates TLR7-dependent systemic autoimmunity,” Cell Host & Microbe, vol. 25, no. 1, pp. 113–127, 2019.
View at: Publisher Site | Google Scholar
M. R. Edwards, R. Dai, B. Heid et al., “Commercial rodent diets differentially regulate autoimmune glomerulonephritis, epigenetics and microbiota in MRL/lpr mice,” International Immunology, vol. 29, no. 6, pp. 263–276, 2017.
View at: Publisher Site | Google Scholar
L. Abdelhamid, X. Cabana-Puig, B. Swartwout et al., “Retinoic acid exerts disease stage-dependent effects on pristane-induced lupus,” Frontiers in Immunology, vol. 11, p. 408, 2020.
View at: Publisher Site | Google Scholar
B. M. Johnson, M. C. Gaudreau, M. M. Al-Gadban, R. Gudi, and C. Vasu, “Impact of dietary deviation on disease progression and gut microbiome composition in lupus-prone SNF1 mice,” Clinical and Experimental Immunology, vol. 181, no. 2, pp. 323–337, 2015.
View at: Publisher Site | Google Scholar
D. L. Fabrizio and S. Yehuda, “The microbiome in autoimmune diseases,” Clinical and Experimental Immunology, vol. 195, pp. 1–44, 2019.
View at: Publisher Site | Google Scholar
P. Konieczna, C. A. Akdis, E. M. M. Quigley, F. Shanahan, and L. O’Mahony, “Portrait of an immunoregulatory bifidobacterium,” Gut Microbes, vol. 3, no. 3, pp. 261–266, 2012.
View at: Publisher Site | Google Scholar
S. L. Gorbach, “Probiotics and gastrointestinal health,” American Journal of Gastroenterology, vol. 95, no. 1, pp. 2–4, 2000.
View at: Publisher Site | Google Scholar
E. A. Griffiths, L. C. Duffy, F. L. Schanbacher et al., “In vivo effects of bifidobacteria and lactoferrin on gut endotoxin concentration and mucosal immunity in Balb/c mice,” Digestive Diseases and Sciences, vol. 49, no. 4, pp. 579–589, 2004.
View at: Publisher Site | Google Scholar
J. N. Manirarora, M. M. Kosiewicz, and P. Alard, “Feeding lactobacilli impacts lupus progression in (NZBxNZW)F1 lupus-prone mice by enhancing immunoregulation,” Autoimmunity, vol. 53, no. 6, pp. 323–332, 2020.
View at: Publisher Site | Google Scholar
Z. Yin, G. Bahtiyar, N. Zhang et al., “IL-10 regulates murine lupus,” Journal of Immunology, vol. 169, no. 4, pp. 2148–2155, 2002.
View at: Publisher Site | Google Scholar
T. R. Chiaro and J. L. Round, “Fiber puts Lactobacillus to SLEep,” Cell Host & Microbe, vol. 25, no. 1, pp. 3–5, 2019.
View at: Publisher Site | Google Scholar
V. Ganapathy, M. Thangaraju, P. D. Prasad, P. M. Martin, and N. Singh, “Transporters and receptors for short-chain fatty acids as the molecular link between colonic bacteria and the host,” Current Opinion in Pharmacology, vol. 13, no. 6, pp. 869–874, 2013.
View at: Publisher Site | Google Scholar
C. Mckenzie, J. Tan, L. Macia, and C. R. Mackay, “The nutrition- gut microbiome- physiology axis and allergic diseases,” Immunological Reviews, vol. 278, no. 1, pp. 277–295, 2017.
View at: Publisher Site | Google Scholar
A. Bankole, X. Luo, and Z. Husen, “A comparative analysis of gut microbiota between systemic lupus erythematosus patients and non-autoimmune controls: a single CentreCenter cohort experience,” Lupus Science and Medicine, vol. 4, 2017.
View at: Publisher Site | Google Scholar
N. O. Kaakoush, “Insights into the role of Erysipelotrichaceae in the human host,” Frontiers in Cellular and Infection Microbiology, vol. 5, p. 84, 2015.
View at: Publisher Site | Google Scholar
C. Gordon, M. L. Stoll, and J. Gavalchin, “Systemic lupus erythematosus — messages from experimental models,” Br Soc Rheumatol, vol. 39, 2000.
View at: Publisher Site | Google Scholar
X. M. Luo, M. R. Edwards, Q. Mu et al., “Gut microbiota in human systemic lupus erythematosus and a mouse model of lupus,” Applied and Environmental Microbiology, vol. 84, no. 4, Article ID e02288, 2018.
View at: Publisher Site | Google Scholar
S. V. Jargin, “Soy and phytoestrogens: possible side effects,” German medical science: GMS e-journal, vol. 12, pp. 18–5, 2014.
View at: Publisher Site | Google Scholar
X. M. Luo, M. R. Edwards, C. M. Reilly, Q. Mu, and S. A. Ahmed, in Diet and Microbes in the Pathogenesis of Lupus, IntechOpen, London, UK, 2017.
View at: Publisher Site
P. Guo, K. Zhang, X. Ma, and P. He, “Clostridium species as probiotics: potentials and challenges,” Journal of Animal Science and Biotechnology, vol. 11, pp. 24–10, 2020.
View at: Publisher Site | Google Scholar
M. A. Zimmerman, N. Singh, P. M. Martin et al., “Butyrate suppresses colonic inflammation through HDAC1-dependent fas upregulation and fas-mediated apoptosis of T cells,” American Journal of Physiology - Gastrointestinal and Liver Physiology, vol. 302, no. 12, Article ID G1405, 2012.
View at: Publisher Site | Google Scholar
Z. He, T. Shao, H. Li, Z. Xie, and C. Wen, “Alterations of the gut microbiome in Chinese patients with systemic lupus erythematosus,” Gut Pathogens, vol. 8, no. 1, p. 64, 2016.
View at: Publisher Site | Google Scholar
J. W. Kim, S. K. Kwok, J. Y. Choe, and S. H. Park, “Recent advances in our understanding of the link between the intestinal microbiota and systemic lupus erythematosus,” International Journal of Molecular Sciences, vol. 20, no. 19, pp. 4871–4913, 2019.
View at: Publisher Site | Google Scholar
T. Chinen and A. Y. Rudensky, “The effects of commensal microbiota on immune cell subsets and inflammatory responses,” Immunological Reviews, vol. 245, no. 1, pp. 45–55, 2012.
View at: Publisher Site | Google Scholar
Y. Ma, R. Guo, Y. Sun et al., “Lupus gut microbiota transplants cause autoimmunity and inflammation,” Clin Immunol., vol. 233, 2021.
View at: Publisher Site | Google Scholar
Z. He, X. Kong, T. Shao, Y. Zhang, and C. Wen, “Alterations of the gut microbiota associated with promoting efficacy of prednisone by bromofuranone in MRL/lpr mice,” Frontiers in Microbiology, vol. 10, p. 978, 2019.
View at: Publisher Site | Google Scholar
H. M. Roager and T. R. Licht, “Microbial tryptophan catabolites in health and disease,” Nature Communications, vol. 9, no. 1, pp. 3294–3310, 2018.
View at: Publisher Site | Google Scholar
T. Sasaki-imamura, Y. Yoshida, K. Suwabe, F. Yoshimura, and H. Kato, “Molecular basis of indole production catalyzed by tryptophanase in the genus Prevotella,” FEMS Microbiology Letters, vol. 322, no. 1, pp. 51–59, 2011.
View at: Publisher Site | Google Scholar
C. Lood, H. Tydén, B. Gullstrand et al., “Type I interferon-mediated skewing of the serotonin synthesis is associated with severe disease in systemic lupus erythematosus,” PLoS One, vol. 10, no. 4, Article ID e0125109, 2015.
View at: Publisher Site | Google Scholar
A. Hevia, C. Milani, P. López et al., “Intestinal dysbiosis associated with Systemic Lupus Erythematosus,” mBio., vol. 5, no. 5, pp. 1–10, 2014.
View at: Publisher Site | Google Scholar
Z.-Y. Pan, Y.-X. Chang, N. Han et al., “Short-Term high-dose gavage of hydroxychloroquine changes gut microbiota but not the intestinal integrity and immunological responses in mice,” Life Sciences, vol. 264, Article ID 118450, 2021.
View at: Publisher Site | Google Scholar
E. Angelakis, M. Million, S. Kankoe et al., “Abnormal weight gain and gut microbiota modifications are side effects of long-term doxycycline and hydroxychloroquine treatment,” Antimicrobial Agents and Chemotherapy, vol. 58, no. 6, pp. 3342–3347, 2014.
View at: Publisher Site | Google Scholar
T. Matsuda, N. T. M. Ly, N. Kambe et al., “Early cutaneous eruptions after oral hydroxychloroquine in a lupus erythematosus patient: a case report and review of the published work,” The Journal of Dermatology, vol. 45, no. 3, pp. 344–348, 2018.
View at: Publisher Site | Google Scholar
M. Guo, H. Wang, S. Xu et al., “Alteration in gut microbiota is associated with dysregulation of cytokines and glucocorticoid therapy in systemic lupus erythematosus,” Gut Microbes, vol. 11, no. 6, pp. 1758–1773, 2020.
View at: Publisher Site | Google Scholar
H. Neuman and O. Koren, “The gut microbiota: a possible factor influencing systemic lupus erythematosus,” Current Opinion in Rheumatology, vol. 29, no. 4, pp. 374–377, 2017.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2022 Prisly Z. Putri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

879

Downloads

737

Citations